MYP_002300
Faricimab
Anticancer
Immunology
▸
Immune modulation
▸
Immunomodulatory activity
Therapeutic / Biomedical activity
▸
Enzyme replacement therapy
Standard
450 amino acids
C2192H3385N575O679S15
Standard
QVQLVQSGAEVAKPGTSVKLSCKASGYTFTDYWMQWVKQRPGQGLEWIGTIYPGDGDTGYAQKFQGKATLTADKSSKTVYMHLSSLASEDSAVYYCARGDYYGSNSLDYWGQGTSVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK
49137.75 Da
8.33
4.54
3.54
0.0101
-0.44
0.55
0.01
41.54
67.91
0.0956
82280.00
82905.00
The radar chart summarizes major physicochemical dimensions for quick comparison, while exact numerical values remain listed on the left.
Amino Acid Composition
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber in the current view mode. Use the buttons to zoom.
2D CHEMICAL STRUCTURE
Drag to move
Drag to move. Use the buttons to zoom.
RECORD: Rec_0139820
VERIFIED: NO
Provenance & Taxonomy
synthetic construct [Synthetic]
Monoclonal antibody
9606
Structure & Mods
linear peptide/protein therapeutic [Linear]
canonical L-amino-acid peptide [L]
Phosphorylation
Bio-Activity Profile
Immunomodulatory
VEGF-A; angiopoietin-2 (Ang-2)
RECORD: Rec_0244227
VERIFIED: NO
Provenance & Taxonomy
synthetic construct [Synthetic]
Monoclonal antibody
10029
Structure & Mods
linear peptide/protein therapeutic [Linear]
canonical L-amino-acid peptide [L]
Bio-Activity Profile
Anticancer
Immunomodulatory
EGFR; MET
The terminal half life of amivantamab-vmjw is 11.3 ± 4.53 days.[L34193]
RECORD: Rec_0427159
VERIFIED: NO
Provenance & Taxonomy
synthetic construct [Synthetic]
Monoclonal antibody
10029
Structure & Mods
linear peptide/protein therapeutic [Linear]
canonical L-amino-acid peptide [L]
Bio-Activity Profile
Anticancer
Immunomodulatory
CD38